Drug profile · INN
prochlorperazine edisylate
PROCHLORPERAZINE EDISYLATE
prochlorperazine edisylate (PROCHLORPERAZINE EDISYLATE) is a dopamine d2 receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — prochlorperazine edisylate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
prochlorperazine edisylate (PROCHLORPERAZINE EDISYLATE) is a dopamine d2 receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine D2 receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is prochlorperazine edisylate?
prochlorperazine edisylate (PROCHLORPERAZINE EDISYLATE) is a dopamine d2 receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for prochlorperazine edisylate?
PROCHLORPERAZINE EDISYLATE is a marketed brand name for prochlorperazine edisylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of prochlorperazine edisylate?
prochlorperazine edisylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.